Home ›
Liver Cancer Trials ›
NCT05484908
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.
Trial Details
NCT ID NCT05484908
Phase NA
Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Status RECRUITING
Cancer Type Liver Cancer
Interventions DPMAS+LPE PE Comprehensive internal medical treatment
Locations (sample) Guangzhou, Guangdong, China|23.11667,113.25
Key Eligibility Criteria
Age from 18 to 65 years old; Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA \> 0.5 year); Clinical diagnosis of hepatocellular carcinoma and receive immune checkpoint inhibitors treatment. The last treatment of immune checkpoint inhibito… The level of hepatitis b virus DNA \< 2000 IU/mL;
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Liver Cancer Trials on Trialify →